This degree responds to an identified need for more NHS pharmacists to engage in research linked to their professional and practice role in areas where a PhD research programme may not be the most appropriate qualification.
The DPharm fits with all areas of the practice of pharmacy including hospital clinical pharmacy, technical services and community pharmacy practice. The programme aims to develop, strengthen and enhance pharmacy research and help to build the credibility of pharmacy as a research focussed profession.
This course is suitable for pharmacists who already have some research experience and wish to enhance their research skills and experience.
The course is either a minimum of three years full-time or four years part-time study.
One third of the course is taught and two thirds is research-based. The taught classes are:
- Clinical skills
- Research skills including health service skills & protocol design
- Literature review
When does teaching begin?
The teaching will take place in the academic year starting at the beginning of October each year.
If you're undertaking the course on a full-time basis all the taught classes will take place in the first year of the course. For part-time students this will take 18 months. The taught classes must be passed to proceed to the research element.
Can I get credit for previous learning?
This may be awarded on an individual basis at the point of application. Any recognised prior learning must be ratified by the Board of Study. Credit for prior leaning may only be awarded in blocks of 60 credits (60, 120 or 180). Only under exceptional circumstances will a student be awarded 180 credits for prior learning.
Will the minimum duration of study be reduced if I get credit for prior learning?
There may be a reduction in the minimum duration of study if credit is given for prior learning but this will be awarded on an individual basis following application and discussion between the DPharm course organiser and the head of Institute. This must also be ratified by the Faculty of Science Board of Study.
What is the final assessment?
Once you have completed all the taught elements and the research, you'll submit a thesis which will be sent to an external examiner (outwith the University of Strathclyde) and an internal examiner (within Strathclyde Institute of Pharmacy and Biomedical Sciences, who is GPhC registered). You'll be called for an oral exam in which you'll defend your thesis and the work that it contains. The examiners will make the decision on whether you should be awarded the qualification.
How will I know if my proposed project will be suitable for a DPharm?
On application you'll be asked to submit your research idea. This can then be discussed with a potential supervisor. Alternatively you can discuss research ideas informally with a potential supervisor before application.
If I have no project idea but want to do the DPharm will you allocate me a suitable project?
The DPharm is linked to your professional practice so it's expected that when you apply you'll have a suitable project idea. Staff at the university may have ideas to help you develop your practice.
What does the research involve?
The research in the DPharm must be linked to professional practice and should normally be undertaken at your place of work. It should be related to the role you have as a pharmacist. Areas of research that may be suitable include clinical practice in hospital or community pharmacy, technical services or a combination of both. This is not an exhaustive list and if you are interested in studying for a DPharm and have an idea for research then you should contact Dr Boyter for further information.
Your research must original and at doctoral level that is suitable for publication in a quality research journal.
PhD Automated microfluidic anticancer drug screening of human tumour biopsies.
A 36-month full-time, fully-funded PhD, supported by the University of Strathclyde and AMS Biotechnology (Europe) Ltd, focusing on the automation of a microfluidic platform for screening human tumour tissue biopsies and developing in vitro immunotherapy assays.
Deadline:2 March 2018
PhD Miniaturised 3D biomedical imaging: multimodal miniature microscope development
A 42-month fully-funded PhD, offered by the University of Strathclyde and working within a Royal Academy of Engineering Research Fellowship programme, focusing on the development of miniaturised biomedical imaging systems using a combination of MEMS micromirrors, fluorescence microscopy and photoacoustic microscopy.
Deadline:31 March 2018
PhD Microfluidic technologies for investigating vascular cell physiology
A 36-month full-time, fully funded PhD, supported by the University of Strathclyde in partnership with AMS Biotechnology (Europe) Ltd, focusing on microfluidic technologies for investigating vascular call physiology
Deadline:2 March 2018
Inhibiting amyloid development using natural compounds: a molecular dynamics study
This project will utilise molecular dynamics simulation, exploiting the ARCHIE_WeSt supercomputer at Strathclyde to understand how the inhibitors interact with protein aggregates; how they interfere with the nucleation and growth pathway of the fibrils, and if aggregation can be reversed.
Investigation of pharmaceutical crystallisation using small angle x-ray scattering
The project will focus on the applications of latest Small-angle X-ray scattering system in CMAC (EPSRC Centre of excellence in continuous manufacturing and crystallisation) to provide mechanistic understanding of interparticle interaction in dense system under repulsive or attractive interactions.
Development of multi-sensor measurement for characterizing biological suspensions and tissue
The project will focus on the development of novel multi-sensor measurement-analysis platform which integrate optics (instrument configuration) and theories of light propagation through particulate media to extract physical and chemical information of biological suspensions.
Role of building design in house dust mite colonization and development of asthma
The questions will be addressed: 1. What are the main factors affecting HDM colonisation and metabolic activity across the Scottish housing stock? 2. Are 'tight' modern house types (lightweight timber frame with polythene vapour barriers) more prone to HDM infestation than traditional heavyweight dwellings?
A multidisciplinary approach to elucidate the mechanism of ammonium transport by the ubiquitous family of Amt/Rhesus protein
What are the functional features that are important for the ion specificity and ion permeation? What are the structural features that explain the mechanistic difference between Amt (transporter) and Rh (channel)? What are the conformational changes associated with the transport cycle?
A new role for the Gelsolin family in the regulation of G protein-coupled receptors (GPCR) activity
The aim of the project is to explore the role of the Gelsolin family across different GPCR pathways to identify if interaction is unique to PAR4 or a universal regulator of GPCRs.
Age-related and cell-type specific neural information processing
In this proposal, we will test the hypothesis that auditory coding in the primary auditory cortex (A1) is changed with age in a cell-type-specific manner. We will specifically focus on one of major cortical cell groups, GABAergic inhibitory neurons, which are further classified into diverse subtypes.
Smart Hardware-embedded Data Processors for Rapid 3D Ranging & Imaging
The studentship is supported by the Datalab, Photon Forces, Faculty of Science and Faculty of Engineering to cover UK/EU fees and stipends.
Development of novel tumour-targeted nanomedicines for cancer therapy
The student will have the opportunity to learn a wide range of multidisciplinary techniques: synthesis and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy) and in vivo analysis
Deadline:31 October 2018
Development of novel tumour-targeted nanomedicines entrapping nutraceuticals for cancer therapy
The student will have the opportunity to learn a wide range of multidisciplinary techniques: preparation and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy) and in vivo analysis.
Deadline:31 October 2018
Development of novel tumour-targeted, albumin-based nanomedicines for cancer therapy
The student will have the opportunity to learn a wide range of multidisciplinary techniques: synthesis and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy, flow cytometry) and in vivo analysis.